Aurinia Pharmaceuticals AUPH
$14.70 −$0.19 (-1.28%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $14.64 -0.41%
Open$14.69
Prev close$14.89
Day range$14.63 – $14.97
Volume1.34M
Market cap$1.97B
P/E (TTM)6.4
Dividend yield–
Earnings
Average move on report day±8.4%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+10.9%
Worst reaction-31.9%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2025/Q4 | 26 Feb 2026 | Pre Market | ±17.5% | -3.19% | Within range |
| 2025/Q3 | 4 Nov 2025 | Pre Market | ±12.7% | +8.35% | Within range |
| 2025/Q2 | 31 Jul 2025 | Pre Market | ±13.4% | +2.15% | Within range |
| 2025/Q1 | 12 May 2025 | Pre Market | ±16.0% | +1.50% | Within range |
| 2024/Q4 | 27 Feb 2025 | Pre Market | ±18.4% | -5.03% | Within range |
| 2024/Q3 | 7 Nov 2024 | Pre Market | ±14.3% | +10.90% | Within range |
| 2024/Q2 | 1 Aug 2024 | Pre Market | ±16.2% | -4.59% | Within range |
| 2024/Q1 | 2 May 2024 | Pre Market | ±18.2% | -0.58% | Within range |
| 2023/Q4 | 15 Feb 2024 | Pre Market | ±14.6% | -24.47% | Bigger than priced |
| 2023/Q3 | 2 Nov 2023 | Pre Market | ±23.1% | +10.52% | Within range |
| 2023/Q2 | 3 Aug 2023 | Pre Market | ±25.0% | +4.24% | Within range |
| 2023/Q1 | 4 May 2023 | Pre Market | ±20.5% | -2.99% | Within range |
| 2022/Q4 | 28 Feb 2023 | Pre Market | ±21.0% | +9.12% | Within range |
| 2022/Q3 | 3 Nov 2022 | Pre Market | ±21.8% | -31.93% | Bigger than priced |
| 2022/Q2 | 4 Aug 2022 | Pre Market | ±22.1% | +0.24% | Within range |
| 2022/Q1 | 10 May 2022 | None | ±15.1% | -15.00% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$83.70M+13.9% YoY
Operating profit$35.36M+18.9% YoY
Net profit$31.70M+0.5% YoY
Diluted EPS$0.23+0.0% YoY
Free cash flow$46.34M+4.4% YoY
Operating cash flow$46.37M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin90.6%
Operating margin48.6%
Net margin97.7%
Return on equity61.4%
Return on assets46.4%
Return on invested capital53.1%
Current ratio6.12
Liabilities / assets20.4%
Cash & investments$486.88M
Total debt$40.71M
Net cash (debt)$446.18M
Free cash flow / sales55.0%
No comments yet — be the first to weigh in on AUPH.
Sign in to join the discussion.